Ariana Pelosci - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Ariana Pelosci's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Ariana Pelosci
Verified
Editor, Cancer Network
New York
Beats
Ophthalmology
Brussel Sprout Recipes, Snooker
Content
By Ariana Pelosci Verified| ONCOLOGY journal Verified Cultural perceptions, education, or financial status were found to shape attitudes surrounding acupuncture use as an integrative oncology therapy for patients who survived breast cancer, according to a poster presentation from the 2025 Oncology Nursing Society Congress.
By Ariana Pelosci Verified, Tim Cortese| ONCOLOGY journal Verified The FDA has approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for patients with unresectable or metastatic hepatocellular carcinoma, according to a press release from the agency.1The approval was based on results from the phase 3 CheckMate 9DW trial (NCT04039607) assessing nivolumab/ipilimumab vs lenvatinib (Lenvima) or sorafenib (Nexavar).
By Ariana Pelosci Verified| ONCOLOGY journal Verified Cultural perceptions, education, or financial status were found to shape attitudes surrounding acupuncture use as an integrative oncology therapy for patients who survived breast cancer, according to a poster presentation from the 2025 Oncology Nursing Society Congress.
Company Info
Cancer Network
Cancer Network is an online platform focused on providing oncology news and clinical expertise. It serves as a valuable resource for insights on cancer screening, early detection, diagnosis, treatment, and prevention. The platform hosts the journal *Oncology*, which delivers professional content aimed at healthcare providers involved in cancer care. As a comprehensive information hub, Cancer Network offers timely updates on advances in cancer research, treatment modalities, and clinical trials. It features articles and expert commentary on best practices in oncology care, along with educational resources that help healthcare providers stay informed about the latest developments in cancer management. The primary audience includes oncologists, oncology nurses, researchers, and other healthcare professionals seeking authoritative information to enhance patient outcomes.
'+1 516-562-5000